Clinical Trial Results
The latest news about Clinical Trial Results: headlines, AI summaries and the full story from every source.
- EyePoint Pharmaceuticals Reports Third Quarter Results with EPS Miss and Revenue Beat
- Pharvaris Reports Third Quarter Financial Results and Clinical Updates
- Amgen Shares Decline Following Late-Stage Trial Results for Sjögren's Disease Drug
- Capricor Reports Q3 2026 Financial Results and HOPE-3 Clinical Trial Data
- Beam Therapeutics Shares Fall Despite Positive Risto-cel Clinical Trial Results
- Veradermics Reports Q3 2026 Financial Results and Positive Clinical Trial Data
- Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data
- Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026
- Atea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Trial Results and Q3 2026 Financials
- Roivant Sciences Reports Q2 2026 Results with LISRAYA Commercial Launch and Positive Clinical Data
- US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson
- Ocular Therapeutix Outlines Axpaxli NDA Plan for Q4 2026 with Cash Runway Extending into 2028
- Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity
- Arrowhead Pharmaceuticals Reports Significant Reduction in Pancreatitis Rates via Plozasiran
- Verastem Reports Q3 2026 Revenue Growth and Positive Clinical Data for VS-7375
- Elutia Plans FDA Submission for NXT-41X This Quarter Following Successful Clinical Study
- Zai Lab Reports Q3 2026 Financial Results and Clinical Progress
- Envoy Medical Reports Q3 2026 Financial Results and Clinical Progress for Acclaim Implant
- GRAIL Anticipates Early Q1 2027 FDA Decision for Galleri Test and Updates Revenue Growth Outlook
- Xencor Reports Q3 Earnings Beat with Significant Revenue Growth and Positive Clinical Data
- Harmony Biosciences Reports Q3 2026 Net Product Revenue of $268.9 Million Driven by WAKIX Growth
- Nuvectis Pharma Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- BioNTech Reports Q3 2026 Earnings with Profit Turnaround and Oncology Progress
- Recursion Pharmaceuticals Reports Q3 2026 Revenue Growth and Clinical Progress
- Cerus Reports Q3 2026 Revenue Growth Driven by INTERCEPT Fibrinogen Complex
- Tiziana Life Sciences Shares Drop Despite Positive Phase 2a Results for Foralumab
- Edwards Lifesciences PASCAL System Meets Primary Endpoint in CLASP II TR Study
- Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment
- AbbVie Clinical Trial Shows Promising Results for Crohn's Disease Combination Therapy
- Johnson & Johnson Reports 94% Success Rate in Clinical Trial for Shockwave Javelin Catheter
- Johnson & Johnson Reports Lower Mortality Rates for Impella Heart Pump Support
- Novartis Faces Future Patent Cliffs Despite Optimism for Remibrutinib
- Rafael Holdings Reports Q4 Revenue Decline and GAAP EPS Loss
- Merck Reports Q3 Earnings Beat Driven by Keytruda and Gardasil Growth
- Viking Therapeutics Reports Q3 2026 Financial Results and Positive Obesity Pipeline Data
- Viking Therapeutics Outlines $100 Million Average Quarterly Cash Burn Amid Clinical Pipeline Advancement
- Genmab Shares Surge Following Positive Phase 3 Trial Results for Petosemtamab
- Eli Lilly's Retatrutide Demonstrates Superior Weight Loss and A1C Reduction Compared to Ozempic in Phase 3 Trial
- Merck's sacituzumab tirumotecan Reduces Death Risk by 32% in Endometrial Cancer Phase 3 Trial
- Johnson & Johnson Reports Positive Prostate Cancer Drug Trial Results While Microsoft Announces Employee Buyouts
- Amgen's Imdelltra Combination Therapy Reduces Death Risk by 58% in Extensive-Stage Small Cell Lung Cancer
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- Argenx Projects 2026 Operating Expenses at $4 Billion Amid U.S. Expansion Plans
- Midday Market Update: SpaceX Revenue Surge and Super Micro Guidance Boost Stocks
- Moderna's mRNA Pipeline Expansion Drives Growth Potential Beyond COVID-19 Vaccines
- Novo Nordisk's CagriSema Shows 25% Weight Loss in Phase 3 Clinical Trial
- Glaukos Stock Drops Over 13% Amid Insider Sale Despite Positive Trial Data
- Investor Alert: Pomerantz Law Firm Investigates Rafael Holdings, Inc.
- Pomerantz Law Firm Investigates Claims Against ClearPoint Neuro Following Stock Drop
- Investor Alert: Pomerantz Law Firm Investigates Novartis AG for Potential Securities Fraud